FDA Scientists Warn Against Giving More Access to Peptide Drugs

Scientists at the U.S. Food and Drug Administration are warning that seven peptide drugs should not get easier access to patients. They say there is not enough proof that these substances are safe or that they actually work. The warning came out on Monday, June 30, 2026, and puts these scientists at odds with Health Secretary Robert F. Kennedy Jr., who is a big supporter of peptides. The FDA is a government agency that decides which drugs are safe enough for Americans to use.

Peptides are short chains of tiny building blocks called amino acids. Wellness clinics and online sellers have been marketing peptides as a way to build muscle, heal injuries, and slow down aging. However, most peptides have never been tested in large, careful scientific studies called clinical trials. The FDA has already warned that injecting certain peptides — like BPC-157 and TB-500 — can be dangerous. Those two are also banned as doping agents by international sports groups.

Kennedy has spoken publicly about peptides many times. He has called himself a 'big fan' and said he used them on injuries with 'really good effect.' Kennedy leads the Department of Health and Human Services, which oversees the FDA. His positive view of peptides is very different from what the FDA's own scientists are recommending.

At the center of the debate is a special FDA advisory committee that will meet for two days in July. This group of experts will discuss whether to allow special pharmacies, called compounding pharmacies, to mix and sell seven peptides. Compounding pharmacies make custom versions of drugs for patients. The committee's advice will help the FDA make its final decision after the meeting.

The FDA released the list of people on this committee on Monday. At least seven of the members have connections to businesses or clinics that sell or promote peptides. That is very different from past versions of the same committee, which were mostly made up of professors from top universities like Duke, Harvard, and Johns Hopkins. Those earlier panels voted several times against allowing peptides in compounded drugs, saying they were too risky.

The new panel includes doctors and pharmacists who run peptide clinics, sell peptide injections, or advertise peptides online. One member is Tennessee State Senator Bobby Harshbarger, who is also a pharmacist. His mother, U.S. Representative Diana Harshbarger, wrote a letter to Kennedy last year asking him to relax the rules on peptides. Both are members of the Republican Party.

An HHS spokesperson named Emily Hilliard said all committee members went through the same ethics review as other FDA advisory candidates. She said anyone who did not meet the requirements was removed from consideration. Still, outside experts are not convinced the new panel is fair or trustworthy.

Paul Knoepfler, a professor at the University of California, Davis, School of Medicine, studies unproven peptide use. He told The Washington Post, 'It seems RFK Jr. stacked the committee,' meaning he thinks Kennedy picked people who are likely to vote in favor of peptides. Dr. Peter Lurie, a former FDA official, said a 'reputable' panel would normally leave out anyone who could make money based on how the vote goes. These experts worry the new panel could overrule the FDA's own scientists.

The FDA does not have to follow the advice of its advisory committees, but it usually does. The agency's final decision on the seven peptides is expected after the July meeting. Until then, scientists on both sides will be watching closely to see what the committee recommends.